ME Therapeutics Holdings Inc. Announces the Addition of Two New Clinical Consultants to Continue the Advancement of Our Lead Anti-G-CSF Antibody Candidate Towards a First-in-Human Clinical Trial
In This Article:
Vancouver, British Columbia--(Newsfile Corp. - May 29, 2024) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) ("ME Therapeutics" or the "Company"), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of immuno-oncology, is pleased to announce that the Company has engaged two new clinical consultants to help advance our lead anti-G-CSF antibody candidate (h1B11-12) towards a first in-human clinical trial.
Dr. Kate Hanham, PhD, is a clinical trial consultant who has consulted for organizations ranging from start-up biotechnology to some of the top ten pharmaceutical companies. She has provided strategic input at all stages of product development, designed and implemented clinical, regulatory and manufacturing strategies from early development through NDA. Dr. Hanham has held lead responsibilities in critical communications with the FDA and international regulatory agencies. She has also provided assessment of technology, product development and clinical programs for financial groups seeking to invest in biotechnology. Dr. Hanham earned her Ph.D. in biochemistry at the University of Birmingham, England, and was awarded a Wellcome Trust fellowship at Yale University. After receiving a faculty position at Yale, Dr. Hanham moved into private industry where her work experience included Centocor, Repligen and Aviron prior to founding her consulting company in 1996. Dr. Hanham's research career in infectious diseases, applied immunology and vaccine development has provided experience critical to organizations developing a variety of products, including gene and cell therapies, monoclonal antibodies, HIV and other viral vaccines, immune modulating agents and small molecule therapeutics. She has established domestic and international product development programs, implemented complex global clinical trials and quality management systems, designed manufacturing and analytical facilities, and provided effective study salvage support.
Dr. Katherine Morris has over 20 years of experience as a surgical oncologist and solid tumor immunologist. Dr. Morris completed her training at Memorial Sloan Kettering Cancer Center after which she cared for patients with primary and metastatic liver and pancreatic malignancies. Her clinical work motivated and informed her research which focuses on reshaping the tumor immune microenvironment for the treatment of gastrointestinal cancers. Part of her research program was focussed on the role of G-CSF in cancer, and more specifically how blocking G-CSF may be beneficial for cancer treatment. As such, she has a keen interest in seeing our lead anti-G-CSF antibody tested in a clinical setting. Dr. Morris is a standing member of the Cellular Immunotherapy of Cancer study section (2022-2026) at the NIH and previously served as a tenured Professor of Surgery and Vice Chair for Academic and Research Development in the Department of Surgery at The University of Oklahoma Health Sciences Center. She is currently the managing partner of NW Surgical Oncology, LLC, based in Portland Oregon.